Exceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation

Prostate cancer is among the most common types of cancer in men. Early detection and proper medical intervention is crucial to ensuring successful treatment. Here we describe a patient clinically presenting with castrate-resistant prostate carcinoma. Comprehensive genomic profiling identified a PTEN...

Descripción completa

Detalles Bibliográficos
Autores principales: Kmak, Jamie A., Agarwal, Nikita, He, Yuting, Heilmann, Andreas M., Miller, Vincent A., Ross, Jeffrey S., Pal, Sumanta Kumar, Ali, Siraj M., Kilari, Deepak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204854/
https://www.ncbi.nlm.nih.gov/pubmed/32399016
http://dx.doi.org/10.1159/000506625
_version_ 1783530133275017216
author Kmak, Jamie A.
Agarwal, Nikita
He, Yuting
Heilmann, Andreas M.
Miller, Vincent A.
Ross, Jeffrey S.
Pal, Sumanta Kumar
Ali, Siraj M.
Kilari, Deepak
author_facet Kmak, Jamie A.
Agarwal, Nikita
He, Yuting
Heilmann, Andreas M.
Miller, Vincent A.
Ross, Jeffrey S.
Pal, Sumanta Kumar
Ali, Siraj M.
Kilari, Deepak
author_sort Kmak, Jamie A.
collection PubMed
description Prostate cancer is among the most common types of cancer in men. Early detection and proper medical intervention is crucial to ensuring successful treatment. Here we describe a patient clinically presenting with castrate-resistant prostate carcinoma. Comprehensive genomic profiling identified a PTEN inactivating mutation in the patient's tumor. After being heavily pretreated, the patient showed stable disease on everolimus, a PI3K-Akt-mTOR pathway inhibitor.
format Online
Article
Text
id pubmed-7204854
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-72048542020-05-12 Exceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation Kmak, Jamie A. Agarwal, Nikita He, Yuting Heilmann, Andreas M. Miller, Vincent A. Ross, Jeffrey S. Pal, Sumanta Kumar Ali, Siraj M. Kilari, Deepak Case Rep Oncol Case Report Prostate cancer is among the most common types of cancer in men. Early detection and proper medical intervention is crucial to ensuring successful treatment. Here we describe a patient clinically presenting with castrate-resistant prostate carcinoma. Comprehensive genomic profiling identified a PTEN inactivating mutation in the patient's tumor. After being heavily pretreated, the patient showed stable disease on everolimus, a PI3K-Akt-mTOR pathway inhibitor. S. Karger AG 2020-04-27 /pmc/articles/PMC7204854/ /pubmed/32399016 http://dx.doi.org/10.1159/000506625 Text en Copyright © 2020 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Report
Kmak, Jamie A.
Agarwal, Nikita
He, Yuting
Heilmann, Andreas M.
Miller, Vincent A.
Ross, Jeffrey S.
Pal, Sumanta Kumar
Ali, Siraj M.
Kilari, Deepak
Exceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation
title Exceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation
title_full Exceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation
title_fullStr Exceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation
title_full_unstemmed Exceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation
title_short Exceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation
title_sort exceptional response to everolimus in a patient with metastatic castrate-resistant prostate cancer harboring a pten inactivating mutation
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204854/
https://www.ncbi.nlm.nih.gov/pubmed/32399016
http://dx.doi.org/10.1159/000506625
work_keys_str_mv AT kmakjamiea exceptionalresponsetoeverolimusinapatientwithmetastaticcastrateresistantprostatecancerharboringapteninactivatingmutation
AT agarwalnikita exceptionalresponsetoeverolimusinapatientwithmetastaticcastrateresistantprostatecancerharboringapteninactivatingmutation
AT heyuting exceptionalresponsetoeverolimusinapatientwithmetastaticcastrateresistantprostatecancerharboringapteninactivatingmutation
AT heilmannandreasm exceptionalresponsetoeverolimusinapatientwithmetastaticcastrateresistantprostatecancerharboringapteninactivatingmutation
AT millervincenta exceptionalresponsetoeverolimusinapatientwithmetastaticcastrateresistantprostatecancerharboringapteninactivatingmutation
AT rossjeffreys exceptionalresponsetoeverolimusinapatientwithmetastaticcastrateresistantprostatecancerharboringapteninactivatingmutation
AT palsumantakumar exceptionalresponsetoeverolimusinapatientwithmetastaticcastrateresistantprostatecancerharboringapteninactivatingmutation
AT alisirajm exceptionalresponsetoeverolimusinapatientwithmetastaticcastrateresistantprostatecancerharboringapteninactivatingmutation
AT kilarideepak exceptionalresponsetoeverolimusinapatientwithmetastaticcastrateresistantprostatecancerharboringapteninactivatingmutation

Ejemplares similares